Guardian Pharmacy Services, Inc. Class A (GRDN) AI Stock Analysis

• Market Cap: $1.60B
• Dividend Yield: N/A
• Average Volume (3M): 396.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 3,400
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 0.23
• Shares Outstanding: 22,730,590
• 10 Day Avg. Volume: 500,009
• 30 Day Avg. Volume: 396,146
• PEG Ratio: 0.03
• Price to Book (P/B): 8.81
• Price to Sales (P/S): 1.02
• P/FCF Ratio: 30.20
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 1.03
• Enterprise Value/Gross Profit: 5.27
• Enterprise Value/Ebitda: -33.43
• 1Y Price Target: $28.00
• Price Target Upside: 6.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 47 Neutral
• Price Target: ―

Guardian Pharmacy Services, Inc. presents a mixed picture. Strong revenue growth and positive guidance improve the outlook, yet significant profitability and leverage challenges remain. The technical analysis signals a short-term upward trend, but valuation is difficult to assess due to missing key metrics. Overall, the stock's strengths in growth are countered by financial and valuation uncertainties, resulting in a moderate stock score.

Guardian Pharmacy Services, Inc. Class A Business Overview & Revenue Model

Company Description

Guardian Pharmacy Services, Inc. Class A (GRDN) is a leading provider of pharmacy services specializing in long-term care and senior living communities. The company operates in the healthcare sector, offering a comprehensive range of pharmaceutical solutions tailored to meet the unique needs of its clients. GRDN's core services include medication packaging, delivery, and management, ensuring the safe and efficient dispensing of drugs to residents in various care facilities.

How the Company Makes Money

Guardian Pharmacy Services, Inc. generates revenue primarily through the provision of pharmacy services to long-term care and senior living facilities. The company earns money by supplying medications directly to these institutions, where they are responsible for managing the pharmaceutical needs of residents. Key revenue streams include the sale of prescription drugs, consulting services for medication management, and specialized packaging solutions that ensure compliance with healthcare regulations. Significant partnerships with healthcare institutions and insurance providers also contribute to its earnings by facilitating a steady client base and enhancing service delivery. Additionally, GRDN may receive reimbursements from government programs and private insurance for medications dispensed to covered individuals.

Guardian Pharmacy Services, Inc. Class A Financial Statement Overview

Summary

Guardian Pharmacy Services, Inc. faces profitability and leverage challenges. The company has shown positive revenue growth, but operational inefficiencies have led to recent losses. The absence of equity highlights financial risks, yet stable cash flows provide some operational reassurance. Strategic adjustments are needed to improve profitability and balance sheet strength.

Income Statement

Gross profit margin has remained relatively stable while revenue growth has been positive over the years. However, the company faced significant challenges in the latest year, with negative EBIT and net income, highlighting operational inefficiencies and profitability issues.

Balance Sheet

The balance sheet shows high leverage with no stockholders' equity for the past years, indicating significant financial risk. The debt-to-equity ratio cannot be calculated due to zero equity, suggesting potential solvency concerns.

Cash Flow

The company managed to maintain positive operating and free cash flows, indicating decent cash management. However, the free cash flow growth rate is inconsistent, and the reliance on cash flow to sustain operations due to negative net income is a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.33B	1.23B	1.05B	908.91M	792.07M	735.96M
Gross Profit	260.48M	244.37M	208.31M	185.87M	161.26M	147.00M
EBITDA	-41.03M	-43.43M	58.81M	68.15M	46.49M	49.07M
Net Income	-82.22M	-87.29M	23.90M	35.42M	16.31M	19.94M
Balance Sheet
Total Assets	356.33M	320.81M	271.17M	256.11M	235.85M	217.87M
Cash, Cash Equivalents and Short-Term Investments	18.82M	4.66M	752.00K	607.00K	15.01M	6.45M
Total Debt	33.70M	30.13M	61.00M	56.81M	50.43M	58.84M
Total Liabilities	176.66M	170.83M	211.31M	180.19M	182.53M	150.80M
Stockholders Equity	169.56M	142.67M	0.00	0.00	0.00	0.00
Cash Flow
Free Cash Flow	37.92M	41.59M	56.26M	31.75M	49.22M	44.27M
Operating Cash Flow	57.66M	57.96M	70.82M	48.52M	58.50M	52.61M
Investing Cash Flow	-32.25M	-30.41M	-13.44M	-17.90M	-13.15M	-12.18M
Financing Cash Flow	-8.13M	-23.64M	-57.23M	-45.03M	-36.79M	-34.26M

Guardian Pharmacy Services, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSIC	69 Neutral	8.22B	21.79	11.29%	―	2.29%	14.98%
CAH	67 Neutral	36.91B	23.97	-56.13%	1.31%	-1.94%	85.70%
PBH	65 Neutral	3.11B	14.84	11.48%	―	0.63%	4.23%
GRDN	47 Neutral	$1.60B	―	-97.70%	―	―	―
OMI	41 Neutral	407.85M	-0.34	428.07%	―	-17.10%	-2720.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Guardian Pharmacy Services, Inc. Class A Corporate Events

Guardian Pharmacy Sets 2025 Incentive Performance Targets

On March 24, 2025, Guardian Pharmacy Services, Inc. announced the establishment of performance criteria and targets for its 2025 annual cash incentive awards under the 2024 Equity and Incentive Compensation Plan. The performance metrics include company revenue, adjusted EBITDA, and geographic expansion, with varying weightings. Executive officers have specific payout ranges based on achieving threshold, target, and maximum performance goals, impacting their potential earnings for the year.

Guardian Pharmacy Services Reports Strong Q4 2024 Results

Guardian Pharmacy Services, Inc. announced preliminary unaudited financial results for Q4 and full year 2024, showing a strong performance with a 20.5% increase in Q4 revenue driven by organic growth, acquisitions, and increased vaccinations. Despite a decrease in net income due to tax provisions and share-based compensation expenses, the company reported a 30.3% increase in adjusted EBITDA. Guardian provided 2025 guidance with expected revenue between $1.330 billion and $1.350 billion, and adjusted EBITDA between $97.0 million and $101.0 million, indicating a positive outlook for the coming year.